The stock of Syndax Pharmaceuticals Inc (NASDAQ:SNDX) is a huge mover today! About 134,655 shares traded hands or 44.62% up from the average. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has risen 2.23% since March 9, 2016 and is uptrending. It has underperformed by 5.19% the S&P500.
The move comes after 7 months negative chart setup for the $254.09 million company. It was reported on Oct, 12 by Barchart.com. We have $12.42 PT which if reached, will make NASDAQ:SNDX worth $35.57 million less.
Analysts await Syndax Pharmaceuticals Inc (NASDAQ:SNDX) to report earnings on November, 8. After $-0.47 actual earnings per share reported by Syndax Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 42.55% negative EPS growth.
According to Zacks Investment Research, “Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company’s product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.”
More notable recent Syndax Pharmaceuticals Inc (NASDAQ:SNDX) news were published by: Marketwatch.com which released: “Syndax Pharmaceuticals” on June 19, 2014, also Quotes.Wsj.com with their article: “News Syndax Pharmaceuticals Inc.SNDX” published on June 14, 2014, Globenewswire.com published: “Syndax Pharmaceuticals Announces Participation at Four Upcoming Investor …” on September 06, 2016. More interesting news about Syndax Pharmaceuticals Inc (NASDAQ:SNDX) were released by: Marketwatch.com and their article: “Syndax Pharmaceuticals Inc. trading above issue price in Nasdaq debut” published on March 03, 2016 as well as Seekingalpha.com‘s news article titled: “Syndax Pharmaceuticals IPO: Supported By A Strong Syndicate” with publication date: March 01, 2016.
SNDX Company Profile
Syndax Pharmaceuticals, Inc., incorporated on October 11, 2005, is a clinical stage biopharmaceutical firm focused on developing a pipeline of combination therapies in multiple cancer indications. The Companyâ€™s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.